Arrhythmias & electrophysiology
Rationale and design of the anticoagulant therapy after left atrial appendage closure (ATLAAC) trial
Study context
- Population
- Patients with atrial fibrillation who have undergone surgical left atrial appendage closure (LAAC) and remain on oral anticoagulation (OAC); patients with successful closure confirmed by cardiac CT are randomizedplanned enrollment, as of January 18th, 2025, 554 enrolled and 319 randomized · enrolled as of January 18th, 2025 554 · randomized as of January 18th, 2025 319
- Participants
- 1,220 patients
- Planned comparison
- Stopping OAC is noninferior to continuing OAC after surgical LAAC in terms of the primary endpoint
- Primary endpoint
- first occurrence of ischemic stroke, systemic arterial embolism, or major bleeding
- Follow-up
- Expected mean 4 years
Methodological detailsnoninferiority hypothesis, design and rationale publication
- Noninferiority hypothesis
- Design and rationale publication
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Trial status · As of January 18th, 2025
- Enrollment began
- March 2024
- Patients enrolled
- 554
- Patients randomized
- 319
- Recruitment expected to continue
- ≈12 months
Original publication
Rationale and design of the anticoagulant therapy after left atrial appendage closure (ATLAAC) trial. Am Heart J. Published 15 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →